David M. Cross

Identification of <i>N</i>-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design

Paul G. Wyatt, Andrew Woodhead, Valério Berdini et al. · Journal of Medicinal Chemistry · 2008 · 337 citations · Full text

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity

Steven Howard, Valério Berdini, John A. Boulstridge et al. · Journal of Medicinal Chemistry · 2008 · 329 citations · Full text

Drug Target, Pyrazol-4-yl Urea, Clinical Candidate +18

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

Matthew Squires, Ruth E. Feltell, Nicola G. Wallis et al. · Molecular Cancer Therapeutics · 2009 · 171 citations

Chemoprevention Strategy, Cancer Biology, Tumor Biology +16

From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

Alastair Brown, Sophie J. Bradley, Fiona H. Marshall et al. · Cell · 2021 · 87 citations · Full text

Molecular Pharmacology, Neurodegenerative Diseases, Alzheimer's Disease +10

The heat shock protein 90 inhibitor, <scp>AT</scp>13387, displays a long duration of action <i>in vitro</i> and <i>in vivo</i> in non‐small cell lung cancer

Brent Graham, Jayne Curry, Tomoko Smyth et al. · Cancer Science · 2011 · 80 citations · Full text

Tumor Xenografts, Chemoprevention Strategy, Molecular Biology +17